



Press Release

Reallocation of certain shareholdings in Senzime AB (publ)

Uppsala, February 19, 2018. During the period of 19-23 February 2018, a group of major shareholders, including two who are Board Directors of Senzime AB (publ) ("Senzime", "the Company"), will reallocate certain shareholdings. The shares will be reallocated within the group, without any consideration, as a result of a revised and agreed allocation methodology related to a previously closed acquisition.

Background - In May 2016, Senzime acquired the Dutch company Acacia Designs BV. The acquisition was paid for by newly issued Senzime shares. A group of former majority shareholders ("Parties") of Acacia Designs BV, who today hold approximately 35 percent of the number of shares and votes in Senzime, have now jointly agreed to reallocate parts of their shareholding pursuant to a completed arbitration proceeding.

As a result, the shareholders Sorin Brull (Senzime Board Director), Richard Polisner, Stone Bridge Biomedical BV and Philip Siberg (Senzime Chairman of the Board) will transfer a total of 950,000 Senzime shares (corresponding to approximately 2.3 percent of all shares in Senzime) free of charge to shareholder T4 Analytics LLC. The number of shares to be transferred by each Party was calculated based on the pro rata shareholding in Acacia Designs BV, before the company was acquired by Senzime.

The redistribution of shares will take place between 19 and 23 February 2018 and will be reported to Finansinspektionen (Swedish Financial Supervisory Authority) as necessary as required by law.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, lena.soderstrom@senzime.com

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com